Abstract
Prostate cancer (PCa) is the second most commonly diagnosed cancer in men. Successful therapy depends heavily on the clinical indicators (biomarkers) for early detection of the presence and progression of the disease. Current clinical biomarkers for PCa are not ideal, often leading to either overtreatment of an indolent disease or undertreatment of an aggressive type. Advances in molecular techniques have facilitated the discovery of new biomarkers for PCa. This chapter will examine the current status of PCa biomarkers on their diagnostic and prognostic potentials for prediction of disease status and response to drug- or treatment-related toxicities.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
